Selective internal radiation therapy forliver cancer with Y-90 microsphere at Bachmai hospital

Mai Trong Khoa1, Tran Dinh Ha1, Tran Hai Binh1, Pham Van Thai1, Le Chinh Dai1, Pham Cam Phuong1, Nguyen Thanh Hung1, Tran Van Thong1, Pham Minh Thong2, Vu Dang Luu2, Nguyen Xuan Hien2, Ngo Le Lam2, Trinh Ha Chau2,
1 Center for Nuclear Medicine and Cancer tumor, Bach Mai Hospital
2 Department of Diagnostic Imaging, Bach Mai Hospital

Main Article Content

Abstract

SUMMARY


Selective Internal Radiation Therapy (SIRT) for liver cancer is a method to inject Y-90 labeled resin microsphere into the hepatic
arteries supplying the tumor. Cancer cells will be annihilate by irradiation with ionizing radiation emitted from Y-90. Theprocedure has been standardized and applied in treatment of liver cancer patients at the Nuclear Medicine & Oncology Center, Bach Mai hospital.
Aims of study:
- To establish and standardize the procedure of SIRT with Y-90 microsphere for liver cancer.


- To assess initial results of SIRT for liver cancer at The Nuclear medicine & Oncology Center, Bach Mai hospital.
Subject and method: 36 patients with primary or secondary liver cancer confirmation. These patients had been treated with
Y-90 microsphere and follow-up assessments after treatment 1 and 3 months. Descriptive and propective study. Establishing a
standard SIRT with Y-90 microsphere for liver cancer.
Results of study: Procedure of SIRT with Y-90 microsphere for liver cancer has been standardized. Contents of protocol
included indications and contraindications; workflow: Arteriographic assessment to map tumor-perfusing vessels and assess portal vein patency; SPECT with Tc 99m MAA to optimize the treatment planning (by dosimetric evaluation) and evaluate hepatopulmonary shunting; inject Y-90 microsphere into the vessels supplying the tumor, SPECT or PET/CT to evaluate the distribution of Y-90 microsphere; Evaluate the outcomes and safety. The initial treatment results of SIRT forprimary liver cancer patients: more than 80% patients responded with treatment, no patient had complication. AFP level reduced in 77.8% and no change in 22.2% patients, AFP reduced from 4660.3ng/ml to 248.4ng/ml; 72.2% patients mean tumor size was decreased from 7.2 cm to 4.3 cm and was stable in 27.8% patients.The patient with secondary liver cancer from colon cancer: CEAreduced from1000 ng/ml to 40ng/ml, tumor size 7.0 cm reduced to 3,0 cm.
Conclusion: Selective internal radiation therapy with Y-90 microsphere for liver cancer is a new, effective and safe method.
Procedure of the technique was standardized and applied for liver cancer treatment at the Nuclear medicine & Oncology Center, Bach Mai hospital. The initial results show the efficacy and safety of the technique and it should be disseminated for primary and secondary liver cancer treatment.

Article Details

References

TÀI LIỆU THAM KHẢO
1. Mai Trọng Khoa và cs (2014): “Điều trị khối u ác tính tại gan bằng vi cầu phóng xạ y-90”, Hội nghị Ung thư Thành phố Hồ Chí Minh T12/2014.
2. Chow PK et al (2010) “Multicenter phase II study of SIR-sphere plus sorafenib as first line in patients with nonresectable hepatocellular carcinoma: The AsiaPacific Hepatocellular Carcinoma Trials Group Protocol 05 (AHCC05)”, ASCO Annual Meeting, J Clin Oncol 2010; 28 (Suppl 7s): Abs. 4072.
3. D’Avola et al (2009) “A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma”, Hepato-gastroenterology; 56: 1683-1688.
4. Francesco G, Lisa B et al (2011) “EANM procedure guidelines for the treatment of liver cancer and liver metastases with intra-arterial radioactive
compounds”, Eur J Nucl Med Mol Imaging, DOI 10.1007/s00259-011-1812-2.
5. Sangro B et al (2013) “Prognostic Factors and Prevention of Radioembolization-Induced Liver Disease”, Hepatology 2013; 57:1078-1087
6. Gibbs P et al (2015). SIRFLOX: thử nghiệm ngẫu nhiên giai đoạn III so sánh điều trị bước 1 bằng mFOLFOX6 (+bevacizumab) với mFOLFOX6
(+bevacizumab) + liệu pháp xạ trị trong chọn lọc (SIRT) ở bệnh nhân ung thư đại trực tràng di căn gan. Presented at 2015 ASCO Annual Meeting; J Clin Oncol 2015; 33 (Suppl): Abs 3502.